Share on facebook Share on Twitter Share on Google Plus Share This
Back to Results

Treatment for Children with Newly Diagnosed Standard Risk Medulloblastoma


Title

Brain Tumor - Treatment for Children with Newly Diagnosed Standard Risk Medulloblastoma

Therapeutic Area Brain Tumors (Pediatric)
Principal Investigator Michael J. Kelly, MD
Min Age 3 Years
Max Age 21 Years
Gender Both
Contact Jennifer Truong
617-636-8885
More Information http://www.clinicaltrials.gov/

Overview


This study is for people who have a type of cancer called medulloblastoma, which is a kind of childhood brain tumor. This study will look at what will happen if a smaller amount of radiation therapy is given to the brain and spinal cord of children with medulloblastoma. Some patients on this study will be given a standard dose of radiation and others will receive a reduced dose.In addition this study will look at what will happen if the volume of radiation that is given during the “boost dose” of radiation is reduced.  A “boost dose” is extra radiation delivered to the tumor area. Some patients on this study will be given a standard-volume boost, which means that the radiation is targeted at the entire posterior fossa. Other patients will be given a smaller volume boost which means that they will be given radiation targeted more directly to the tumor bed.

Study Details

Inclusion Criteria

  • Diagnosis of Average Risk Medulloblastoma, less than 1.5 cm² tumor remaining after surgery 
  • Adequate kidney, liver, and bone marrow function

Exclusion Criteria

  • Presence of Metastatic disease 
  • Pregnancy or breast-feeding 
  • Previous radiotherapy or chemotherapy other than corticosteroids

Study Requirements

This is a Phase III randomized study for patients with newly diagnosed standard risk medulloblastoma.   Subjects will receive chemotherapy and radiation.  Subjects ages 3 – 7 will be randomized to standard versus reduced dose Craniospinal Radiation Therapy.  After receiving craniospinal radiation, all patients are then randomized to receive standard radiation to the entire posterior fossa versus a reduced dose of radiation to only the tumor bed.   All patients then receive maintenance chemotherapy.
Nurse navigators for cancer patients at Tufts Medical Center.

Are you interested in learning more about this clinical trial?

Send us a message and we'll get back to you with more information.

Request information